CRLBFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Cresco Labs Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 6, 2026
$0.58−0.02 (-3.13%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Cresco Labs statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Medicinal Chemicals & Botanical Products companies for comparison
Valuation
| Measure | Cresco Labs | Industry median |
|---|---|---|
| Market Cap | $289.54M | $164.85M |
| Enterprise Value | $574.87M | $87.06M |
| PS Ratio | 0.44 | 3.60 |
| PB Ratio | 0.85 | 2.03 |
| P/FCF Ratio | 7.67 | 17.44 |
| P/OCF Ratio | 3.97 | 13.32 |
Enterprise value
| Measure | Cresco Labs | Industry median |
|---|---|---|
| EV / Sales | 0.88 | 2.43 |
| EV / EBITDA | 27.74 | 14.69 |
| EV / FCF | 15.23 | 20.97 |
Income (trailing twelve months)
| Measure | Cresco Labs | Industry median |
|---|---|---|
| Revenue | $655.85M | $57.94M |
| Gross Profit | $324.57M | $90.47M |
| Operating Income | -$27.99M | -$21.44M |
| Pretax Income | -$95.42M | -$14.45M |
| Net Income | -$135.41M | -$22.46M |
| EBITDA | $20.73M | -$16.91M |
| EPS (Diluted) | -$0.38 | -$0.83 |
Margins
| Measure | Cresco Labs | Industry median |
|---|---|---|
| Gross Margin | 49.5% | 52.3% |
| Operating Margin | -4.27% | -44.5% |
| Pretax Margin | -14.5% | -13.0% |
| Profit Margin | -20.6% | -39.2% |
| EBITDA Margin | 3.16% | -31.3% |
| FCF Margin | 5.76% | -8.85% |
Returns
| Measure | Cresco Labs | Industry median |
|---|---|---|
| Return on Equity (ROE) | -33.2% | -53.1% |
| Return on Assets (ROA) | -10.6% | -41.0% |
| Return on Invested Capital (ROIC) | -2.90% | -32.0% |
| Return on Capital Employed (ROCE) | -2.55% | -37.8% |
Growth
| Measure | Cresco Labs | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -9.46% | 6.01% |
| FCF Growth (YoY) | -66.6% | 2.34% |
| Revenue Growth (3Y CAGR) | -8.02% | 2.25% |
| Revenue Growth (5Y CAGR) | 6.61% | 6.42% |
Balance sheet
| Measure | Cresco Labs | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $57.90M | $62.42M |
| Total Debt | $431.18M | $120.13M |
| Net Cash (Debt) | -$373.28M | $15.68M |
| Net Cash Per Share | -$0.74 | $0.66 |
| Equity (Book Value) | $340.45M | $48.79M |
| Book Value Per Share | $0.68 | $1.36 |
| Tangible Book Value | -$143.07M | $23.06M |
| Working Capital | $159.09M | $75.77M |
Financial position
| Measure | Cresco Labs | Industry median |
|---|---|---|
| Current Ratio | 2.59 | 3.30 |
| Quick Ratio | 0.96 | 2.39 |
| Debt / Equity | 1.27 | 0.51 |
| Debt / EBITDA | 20.80 | 3.35 |
| Debt / FCF | 11.42 | 5.05 |
| Net Debt / EBITDA | 18.01 | 2.22 |
| Interest Coverage | -0.67 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Cresco Labs | Industry median |
|---|---|---|
| Operating Cash Flow | $72.89M | -$12.35M |
| Capital Expenditures | -$35.14M | -$1.06M |
| Free Cash Flow | $37.75M | -$20.28M |
| FCF Per Share | $0.08 | -$0.42 |
Efficiency
| Measure | Cresco Labs | Industry median |
|---|---|---|
| Asset Turnover | 0.51 | 0.38 |
| Inventory Turnover | 3.64 | 2.67 |
Dividends and yields
| Measure | Cresco Labs | Industry median |
|---|---|---|
| Earnings Yield | -46.8% | -22.7% |
| FCF Yield | 13.0% | -9.07% |
Shares
| Measure | Cresco Labs | Industry median |
|---|---|---|
| Shares Outstanding | 502,755,000 | 58,179,650 |
| Shares Change (YoY) | 2.76% | 11.1% |
| Float | 502,755,000 | 49,173,100 |
| Shares Held by Insiders | 0.00% | 11.6% |
| Shares Held by Institutions | 0.03% | 59.4% |
Taxes
| Measure | Cresco Labs | Industry median |
|---|---|---|
| Income Tax | $44.62M | $91.50K |
Scores
| Measure | Cresco Labs | Industry median |
|---|---|---|
| Altman Z-Score | -0.94 | -0.24 |
| Piotroski F-Score | 2 | 4 |
| Beneish M-Score | -3.59 | -2.62 |
Calculated by StockData from Cresco Labs's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.